018913718

Evox

---

August 13, 2023

Trademark Summary

The trademark evox was filed by Evox Therapeutics Limited, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on November 8, 2023, and received one opposition filed on January 10, 2024 by evoxx technologies GmbH on Likelihood of confusion. the opponent was represented by MICHALSKI HÜTTERMANN & PARTNER PATENTANWÄLTE MBB and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued January 10, 2024

The application was filed in English, and English was also language of all opposition proceedings (French was selected as the second language).

---

Goods And Services

• The mark was filed in class 5 with following description of goods:
  
  1. Pharmaceuticals
  2. Pharmaceutical preparations and substances
  3. Pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use
  4. Pharmaceutical preparations, namely, exosomes to deliver protein or nucleic acids or viral vectors for therapy
  5. Medicine
  6. Medical preparations and articles
  7. Biological preparations for medical purposes
  8. Biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders
  9. Biological preparations comprising exosome
  10. Biological preparations comprising a therapeutic target protein-loaded, nucleic acid-loaded or virus-loaded exosome
  11. Biological preparations comprising exosome for use in the manufacture of pharmaceuticals
  12. Biological reagents for medical use
  13. Mixed biological preparations for medical purposes
  14. Mixed biological preparations for the prevention and treatment of infectious diseases
  15. Diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research
  16. Diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research
  17. Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, EV-based nucleic acid therapeutics for the prevention and treatment of infections or disease
  18. Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection
  19. Diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection
  20. Diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia
  21. Diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders.
• The mark was filed in class 42 with following description of goods:
  
  1. Scientific, medical and pharmaceutical research and development services
  2. Pharmaceutical drug development services
  3. Research and development of pharmaceutical preparations
  4. Biological research
  5. Clinical research
  6. Providing medical and scientific research information in the field of filtration of exosomes from cultured cells or blood
  7. Scientific investigations for medical purposes
  8. Scientific laboratory services
  9. Medical laboratory services
  10. Laboratory research services relating to pharmaceuticals
  11. Research and development in the field of biotherapeutics for the treatment of genetic diseases, cancer, diabetes, obesity, metabolic syndrome and dementia
  12. Research and development in the field of biotherapeutics for the treatment of other aging associated pathologies such as mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders
  13. Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science
  14. Laboratory services for analytical testing
  15. Information, advisory and consultancy services relating to the aforesaid.
• The mark was filed in class 44 with following description of goods:
  
  1. Medical services
  2. Medical and pharmaceutical consultancy
  3. Medical diagnostics
  4. Medical analysis and examinations
  5. Medical treatment services
  6. Medical screening
  7. Medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, viral and bacterial based infections and diseases
  8. Medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome and dementia
  9. Medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders
  10. Information, advisory and consultancy services relating to the aforesaid.